$NanoViricides(NNVC.US$
NEWS
A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides announced that its antiviral drug candidate, NV-387, showed complete survival in mice lethally infected with RSV (Respiratory Syncytial Virus) in a recent study.
The study compared NV-387 with the currently approved RSV treatment, ribavirin. While NV-387 led to the complete survival of animals over a 21-day period, ribavirin resulted in the death of all subjects by day 14.
RSV is a major cause ...
NEWS
A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides announced that its antiviral drug candidate, NV-387, showed complete survival in mice lethally infected with RSV (Respiratory Syncytial Virus) in a recent study.
The study compared NV-387 with the currently approved RSV treatment, ribavirin. While NV-387 led to the complete survival of animals over a 21-day period, ribavirin resulted in the death of all subjects by day 14.
RSV is a major cause ...
$Digihost Technology(DGHI.US$
NEWS
Digihost Announces Record Revenue and $8.9m EBITDA* for Q1 2024
Positive
Record revenue of $12.9 million in Q1 2024, a 216% increase from Q1 2023.
EBITDA of $8.9 million, representing a 255% increase over Q1 2023.
Net income of $4.84 million compared to a net loss of $9.09 million in Q1 2023.
Digital currencies valued at $2.9 million, an increase of 254% from Q1 2023.
Positive working capital balance, indicating good liquidity.
No dilution from the expiratio...
NEWS
Digihost Announces Record Revenue and $8.9m EBITDA* for Q1 2024
Positive
Record revenue of $12.9 million in Q1 2024, a 216% increase from Q1 2023.
EBITDA of $8.9 million, representing a 255% increase over Q1 2023.
Net income of $4.84 million compared to a net loss of $9.09 million in Q1 2023.
Digital currencies valued at $2.9 million, an increase of 254% from Q1 2023.
Positive working capital balance, indicating good liquidity.
No dilution from the expiratio...
1
$Codexis(CDXS.US$
NEWS
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
On May 14, 2024, Codexis (NASDAQ: CDXS) announced a significant milestone in enzymatic synthesis at the TIDES USA annual meeting. The company successfully synthesized a full-length oligonucleotide via its ECO Synthesis™ platform, offering an alternative method for RNA-based therapeutics production. This platform demonstrated coupling efficiency greater than 98% and minimized impurities ...
NEWS
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
On May 14, 2024, Codexis (NASDAQ: CDXS) announced a significant milestone in enzymatic synthesis at the TIDES USA annual meeting. The company successfully synthesized a full-length oligonucleotide via its ECO Synthesis™ platform, offering an alternative method for RNA-based therapeutics production. This platform demonstrated coupling efficiency greater than 98% and minimized impurities ...
$Aurinia Pharmaceuticals(AUPH.US$
NEWS
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the cost-effectiveness of LUPKYNIS® (voclosporin) for treating lupus nephritis (LN) at the National Kidney Foundation Spring Clinical Meeting 2024. The updated analysis, consistent with a 2021 assessment, utilized the ICER AnalyticsTM LN model and found LUPKYNIS ...
NEWS
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the cost-effectiveness of LUPKYNIS® (voclosporin) for treating lupus nephritis (LN) at the National Kidney Foundation Spring Clinical Meeting 2024. The updated analysis, consistent with a 2021 assessment, utilized the ICER AnalyticsTM LN model and found LUPKYNIS ...
已翻譯
1
Jaguar8樓主 72746862: 從長遠來看,公司的生存是必要的。完成發售後,它為其項目和其他開支獲得資金。如果它沒有生存,零售投資者是否有股票可以從他們那裡購買?不。